Alle afleveringen
282 afleveringen, van nieuw naar oud
-
Episode 106 - Gemma Guinart Mola - Principal at Invivo Partners
20 januari 2026 · 21 min
On this episode we're joined by Invivo Partners' Gemma Guinart, for a discussion into early-stage biotech investing. Lees meer
Invivo Partners look to invest in compelling in-vivo proof of concept data, and back founding teams across Europe with pre-seed to Series A investment - recent investments from their third fund include Neumirna Tx & Signadori Bio.
Tune in to hear more about how Gemma & the team identify investment opportunities & why they focus on early-stage investments in a market that has recently leaned toward late-stage de-risked assets.
We also chat briefly through some potential pitfalls for founders looking for funding, their newest fund bridging healthcare & AI, and success stories from the Invivo Partners portfolio, including EsoBiotec.
-
Episode 105 - Ahmet Tutuncu - CEO of AeroRx Therapeutics
15 januari 2026 · 24 min
We're joined by Ahmet Tutuncu, CEO of AeroRx Therapeutics, to discuss their novel, best-in-class nebulized combination product for moderate-to-severe COPD patients. Lees meer
AeroRx's pipeline includes AERO-007, the first nebulized LABA/LAMA combination in clinical development, and AERO-111, the first triple LABA/LAMA/ICS nebulized therapy in IND-enabling studies.
Ahmet previously co-founded Elevation Pharma and Patara Pharma, both acquired for their inhaled-drug platforms.
In a wide ranging discussion we also discuss the deal-making streak in the COPD space, starting with Merck's acquisition of Verona Pharma in mid-2025, and highlighted by the recent launch of AirNexis.
-
Episode 104 - Amir Hefni - CEO of Resolution Therapeutics
5 januari 2026 · 20 min
On this episode we feature the CEO of Resolution Therapeutics, Amir Hefni. Throughout his career, Amir has held roles with global powerhouses such as BMS, Ipsen, & Novartis, before transitioning to small biotech with Resolution in 2023. Lees meer
Resolution's pipeline of regenerative macrophage therapies originates from research out of Edinburgh University. With potential across inflammatory & fibrotic diseases, the team are currently focused on patients with end-stage liver cirrhosis who otherwise only have transplantation as a treatment option.
Tune in to hear more about Resolution's ongoing ph1/2 trials & what to look out for from them in 2026. We also discussed Amir's findings during the transition from big pharma to small biotech, plus the pro's & con's of building in biotech in The UK.
-
Episode 103 - Justin To - CEO of QED Therapeutics, a Bridge Bio Company
19 december 2025 · 15 min
Today’s guest is Justin To, a leader at the forefront of biotech innovation and gene therapy. Justin currently serves as CEO of QED Therapeutics, a BridgeBio company, where he helps guide the development of treatments for rare genetic diseases. Lees meer
With a background that spans strategy consulting at McKinsey, healthcare technology at Flatiron Health, and multiple leadership roles at BridgeBio, Justin brings a unique blend of scientific rigor, operational leadership, and business insight. He’s worked across the full lifecycle of drug development—from early strategy to commercialization—always with a focus on making a real impact for patients with unmet medical needs.
Justin is also a Harvard-trained chemist, graduating magna cum laude with highest honors, and he’s passionate about translating complex science into therapies that can truly change lives.
-
Episode 102 - Miquel Vila-Perello - CEO of SpliceBio
19 december 2025 · 23 min
We recently sat down with Miquel Vila-Perello, CEO of SpliceBio, at Jefferies - during which the team picked up the Series B Raise of the Year at the 2025 ELAs for their $135million round earlier this year. Lees meer
SpliceBio are a Barcelona-based gene therapy company using a proprietary Protein Splicing platform to address diseases caused by large genes that traditional AAV vectors can’t deliver. Their lead program, SB-007 for Stargardt disease, is currently being investigated in their Phase 1/2 ASTRA study, marking a key clinical milestone in a condition with no approved treatments.
It was great to sit down with Miquel and hear about his journey in biotech & the origins of SpliceBio. He also shared some advice for other scientific co-founders stepping into the CEO-hotseat & his take on why Barcelona is well positioned to be the next EU biotech hot-spot.
-
Episode 101 - Jason Cole - CEO of ZagBio
18 december 2025 · 40 min
We were delighted to be joined by Jason Cole, a seasonedbiotechnology executive and the CEO of Zag Bio, a Cambridge-based biotech company taking a novel approach to autoimmune disease, onto The BioHub! Lees meer
Jason brings more than two decades of leadership experience across the biotech industry, spanning company formation, drug development, corporate strategy, and commercialization. Before joining Zag Bio, he heldsenior executive roles at several innovative life-science companies, including bluebird bio, where he served in multiple leadership positions across strategy, operations, finance, and legal affairs. He has also led and advised emerging biotech companies as both a CEO and board member.
At Zag Bio, Jason is leading a bold effort to rethinkhow autoimmune diseases are treated. Their work aims to address the root cause of autoimmunity, with the potential for more durable and transformative therapies.
We’re excited to talk with Jason today about his careerjourney, the science behind Zag Bio, and what it takes to build the next generation of biotech innovation.
-
Episode 93 - Brendan Teehan - CCO Pacira Biosciences
16 december 2025 · 26 min
Today on The BioHub, I’m joined by Brendan Teehan, Chief Commercial Officer at Pacira BioSciences. Lees meer
Brendan has spent three decades building and leading commercial teams across biopharma, from Johnson & Johnson to Amgen, Tesaro, and Acadia.
Now at Pacira, he’s driving the company’s mission to transform pain management through innovative non-opioid therapies.
In this conversation, we get into what inspired him to join Pacira, how the company has evolved, and how they’ve aligned the entire organization around a clear and bold mission. We also dive into leadership, culture, and the future of pain management.
Let’s get into it.
-
Episode 100 - Lance Baldo - CEO of Beacon Therapeutics
16 december 2025 · 16 min
We recently spoke to Lance Baldo, CEO of Beacon Therapeutics, during the Jefferies Healthcare Conference. Lees meer
Beacon's Vista ph3 trial for laru-zova, their AAV Gene Therapy for X-Linked Retinitis Pigmentosa, has completed enrolment with topline expected in mid-2026.
Listen in to hear about Lance's career, from roles with Roche in both Switzerland & New Zealand to a return to the US with Genentech's ophthalmology division, and how he's drawn on those experiences in his role as CEO of Beacon.
We also cover Lance's experience as a first-time CEO, and his advice for other executives making that transition, on topics as broad as fundraising, regulatory discussions, and team building.
And of course, we cover the story behind Beacon & their mission to deliver a step-change for XLRP patients globally.
-
Episode 99 - Luba Greenwood - CEO Gallop Oncology
15 december 2025 · 38 min
Welcome to The BioHub Podcast. Lees meer
I’m joined by Luba Greenwood, CEO of Gallop.
Luba’s one of the most respected voices in biotech — a three-time CEO, founder of Binney Street Capital at Dana-Farber, and a driving force behind Biotech Hangout.
We talk about Gallop’s mission, what it takes to build strong culture in tough markets, and the personal motivation behind her work after losing her mum to cancer.
It’s an inspiring and powerful conversation — let’s get intoit.
-
Episode 98 - Christian Leisner - CEO CDR Life
9 december 2025 · 19 min
Today we’re joined by a leader at the forefront of next-generation immunotherapy — Dr. Christian Leisner. Christian is the CEO and co-founder of CDR-Life, a biotechnology company pioneering a new class of highly targeted T-cell engaging therapies designed to tackle some of the most difficult-to-treat cancers. Lees meer
With a PhD in Biochemistry from ETH Zurich and a Master’s in Molecular Biology and Chemistry from Roskilde University in Denmark, Christian has built a career that bridges deep scientific expertise with strategic leadership. Before launching CDR-Life, he held key roles at Novartis, Alcon, and the biotech success story ESBATech, contributing to global development programs across oncology, ophthalmology, autoimmunity, and cardiovascular disease.
Today, Christian leads CDR-Life’s mission to unlock the potential of MHC-targeted immunotherapies — developing treatments designed to precisely attack tumor cells by recognizing intracellular antigens, long thought to be ‘undruggable.’ Under his leadership, the company is shaping what could become a transformational approach in the fight against cancer.
We’re thrilled to have him with us today to explore the science, the strategy, and the future of immunotherapy
-
Episode 97 - Christina Coughlin - CEO Avacta Therapeutics
5 december 2025 · 31 min
We were delighted to welcome Dr. Christina Coughlin, CEO of Avacta Therapeutics, onto The BioHub! Avacta are a clinical-stage biotech pioneering next-generation oncology therapies. Lees meer
With a remarkable career spanning top pharmaceutical companies and cutting-edge biotech — from Immunocore and Rubius Therapeutics to Tmunity and CytoImmune — Christina brings a unique blend of medical expertise, scientific insight, and leadership acumen. At Avacta, she is driving the development of groundbreaking therapeutics, leveraging proprietary platforms like pre|CISION™, with the goal of bringing life-changing treatments from lab to clinic.
In this episode, we’ll explore her journey from clinician-scientist to biotech executive, the vision and science behind Avacta, and the challenges and opportunities in developing innovative cancer therapies in today’s evolving regulatory and commercial landscape.
-
Episode 96 - Jill Howe - CFO Lineage Cell Therapeutics
3 december 2025 · 26 min
Welcome to another Episode of The Biohub Lees meer
Today, I’m joined by Jill Howe, Chief Financial Officer at Lineage Cell Therapeutics, a company developing groundbreaking allogeneic cell therapies for conditions like dry AMD, spinal cord injury, and hearing loss.
Jill’s career spans more than 20 years across some of biotech’s most successful companies, helping take both Receptos and Gossamer Bio public before stepping into her current role at Lineage.
We talk about what inspired her to join the company, how shehelps shape and protect Lineage’s culture, what excites her most about their pipeline, and her perspective on leadership and women in biotech.
Let’s get into it.
-
Episode 95 - Abigail Jenkins
3 december 2025 · 31 min
Welcome back to another episode of The BioHub, we were thrilled to introduce a guest whose career lies at the cutting edge of cell therapy, biotech leadership, and real-world impact. Abigail Jenkins is a visionary biotech CEO whose journey has taken her from pioneering the development of cell therapies to leading companies at the forefront of regenerative medicine. Lees meer
Before stepping into her current role, Abigail served as CEO of Gamida Cell, where she guided the company through pivotal stages of clinical development, advanced its pipeline of therapies, and championed innovation in cell-based treatments for patients in need. Her leadership helped bring new hope to people suffering from life-threatening diseases — all while navigating the complexities of regulatory approval, scientific uncertainty, and market pressures.
-
Episode 94 - Cameron Turtle - CEO of Spyre Therapeutics
1 december 2025 · 22 min
On this episode we welcomed Cameron Turtle, CEO of Spyre Therapeutics during the Jefferies Healthcare conference. Lees meer
Spyre are developing next-generation antibodies, engineered for prolonged activity in the body and formulated for delivery as monotherapies or combination therapies to validated inflammatory targets. Their approach has the potential to deliver uncompromising efficacy and convenience for patients in a number of autoimmune indications.
This podcast was recorded in November 2025. Comments made during this podcast contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to Spyre Therapeutic, Inc.'s (“Spyre”) expectations regarding Spyre’s product candidates including their potential safety and efficacy, business and clinical trial plans, milestones and timelines. All statements other than statements of historical fact are forward-looking statements and are subject to numerous risks and uncertainties that could cause actual results to differ materially from those expressed in any forward-looking statements. For further details concerning these risks and uncertainties, please refer to Spyre's SEC filings, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q. These forward-looking statements are only as of the date they were made and are qualified in their entirety by reference to the cautionary statements herein. Spyre does not undertake or accept any duty to make any updates or revisions to any forward-looking statements.
-
Episode 92 - Luc Dochez - Managing Partner at Droia Ventures
25 november 2025 · 33 min
Today we’re joined by one of Europe’s most respected builders of biotechnology companies — Luc Dochez.
Luc is a scientist-turned-entrepreneur whose career has helped shape the next generation of therapies in oncology, rare diseases, and genetic medicine. Over the past two decades, he has co-founded and led multiple biotech companies, including Vico Therapeutics, Montis Biosciences, and Pharvaris, and he served as CEO of Tusk Therapeutics, guiding it all the way to its acquisition by Roche. Lees meerBefore becoming a serial entrepreneur, Luc held senior leadership roles at Prosensa, TiGenix, and other pioneering biopharma firms, building a reputation for turning cutting-edge science into real therapeutic opportunities. Today, as a Managing Partner at DROIA Ventures, he invests in and mentors the startups pushing the boundaries of precision medicine.
With a background that spans pharmacy, business strategy, company formation, and venture capital, Luc brings a uniquely holistic perspective on how breakthrough therapies go from idea to impact.
-
Episode 91 - Sten Sörensen - Cereno Scientific
24 november 2025 · 18 min
-
Episode 90 - Andrea DiMella - Atlas Venture
14 november 2025 · 42 min
On this episode we're joined by Andrea DiMella - VP & Head of Talent at Atlas Venture - to get her insight into the evolving talent landscape in biotechnology. Lees meer
We talk through Andrea's transition from a laboratory scientist into a transformative TA leader through roles with Genentech, Biogen, Third Rock, and now Atlas Venture. Her learnings throughout this journey are shaping the TA strategy of some of the most exciting biotechs in the Atlas portfolio.
Tune in to hear more about Andrea's perspective on building influential teams & company creation, when to provide hands-on support & when to let C-teams 'fly solo', and of course, Andrea's take on AI in talent acquisition.
-
Episode 89 - Rita Balice-Gordon - Muna Therapeutics
12 november 2025 · 25 min
Rita is the CEO of Muna Therapeutics, a biotech company focused on discovering and developing therapies that restore the function of diseased neurons and slow or stop neurodegeneration. Lees meer
In this conversation, we explore Rita’s career journey and what inspired their move into biotech leadership, as well as what first drew them to Muna Therapeutics. We talk about Muna’s scientific focus, how their approach to neurodegenerative diseases stands apart, and what it takes to lead a globally distributed team.
We also dive into the culture they’re building at Muna — one that encourages innovation and resilience — and look ahead at what’s next for the company over the coming year.
-
Episode 88 - Robert Hoffman - CFO Cytodyn
11 november 2025 · 29 min
Today on The BioHub, I’m joined by Robert Hoffman, Chief Financial Officer of CytoDyn. Lees meer
Robert is a true industry veteran — with decades ofexperience leading finance and strategy across some of biotech’s most recognizable names, from Arena to Heron and Kintara. Over his career he’s guided IPOs, spin-offs, fundraises, and M&A, all while serving on the boards of multiple biotech companies.
Now at CytoDyn, Robert is helping steer the company as itadvances its lead monoclonal antibody program.
This conversation is about leadership, staying motivated inbiotech’s toughest cycles, and the big vision for CytoDyn’s future.
-
Episode 87 - Sheila Gujrathi
11 november 2025 · 34 min
Today, we’re joined by an extraordinary leader who has spent her career at the intersection of science, innovation, and human potential — Dr. Sheila Gujrathi. Lees meer
Sheila is a physician, scientist, engineer, and biotech entrepreneur whose journey embodies both precision and purpose. She earned her Bachelor’s degree in Biomedical Engineering and her M.D. from Northwestern University, before completing her residency at Brigham and Women’s Hospital / Harvard Medical School and fellowships in Allergy and Immunology at UCSF and Stanford.
Her career has been defined by bold leadership and groundbreaking innovation — from leading global immunology programs at Bristol-Myers Squibb, to serving as Chief Medical Officer at Receptos, where she helped advance the drug Zeposia® to approval for multiple sclerosis and ulcerative colitis. She went on to co-found and serve as CEO of Gossamer Bio, and today she chairs the boards of Ventyx Biosciences and Lila Biologics, while serving as a director at Janux Therapeutics.
But beyond her professional success, Sheila is known for her authenticity, her advocacy for diversity and inclusion in biotech, and her belief in leading with empathy, curiosity, and courage. Through her writing and mentorship, she challenges us to bring our whole selves to our work — reminding us that science and leadership are at their best when they’re deeply human.
-
Episode 86 - David de Vries - Tr1X
7 november 2025 · 24 min
On this episode we're joined by the Co-Founder & CEO of Tr1X, David de Vries. Lees meer
David and the team are building on the Nobel Prize winning research into T-reg cells of Fred Ramsdell, Shimon Sakaguchi, and Mary Brunkow, pushing that science forward by translating a Type-1 regulatory T cell program into the clinic with one goal - lasting immune balance for patients.
Their lead program TRX103 is in ph1/2 trials for GvHD and Refractory Crohn's, whilst they just received another IND clearance for TRX319, an allogeneic CD19 CAR-Tr1 therapy, to tackle Progressive MS. Tr1X pick hard problems on purpose & these indications demonstrate that.
David is an impressive leader, having co-founded Arine, and was nominated recently in BioSpace's 40 under 40 list. Tr1X are one to watch, we hope you'll enjoy the episode!
-
Episode 85 - Neha Krishnamohan - CFO & EVP Corporate Development at Artiva Biotherapeutics
6 november 2025 · 27 min
We were honoured to welcome Neha Krishnamohan, onto The BioHub. Lees meer
Neha began her professional journey at Goldman Sachs in theHealthcare Investment Banking Group, focusing on mergers & acquisitions and strategic financings for biotech and med-tech companies. During her time there, she helped execute more than $100 billion in transactions across biopharma, diagnostics and tools.
Building on that foundation, Neha then moved into anoperational leadership role in biotech: she served as CFO and Executive Vice President of Corporate Development at Kinnate Biopharma, a precision-oncology company, where she led financial operations, business development and investor relations — working through strategic alternatives that culminated in asset transactions and acquisition.
Most recently, she joined Artiva Biotherapeutics, aclinical-stage company focused on off-the-shelf natural-killer (“NK”) cell therapies for autoimmune diseases and cancer, as CFO & EVP Corporate Development (April 2024). Her role is helping drive the company’s growthstrategy, financing, M&A and operational execution as Artiva scales its pipeline.
-
Episode 84 - Tord Labuda - CEO of Alzinova
30 oktober 2025 · 22 min
On this episode of the BioHub Podcast we’re joined by the CEO of Alzinova, Tord Labuda. Alzinova are a Gothenburg-based biotech developing an Alzheimer’s vaccine that's just received FDA IND approval and will soon step into ph2 trials. Lees meer
Alzinova’s products have been developed using their proprietary AβCC peptide™ technology. The technology entails covalent restriction of the amyloid-β (Aβ) peptide so that it only forms the soluble (Aβ) toxins (oligomers/protofibrils) that play a central role in the disease process.
Alzinova's mission is to bring true disease-modifying therapy to Alzheimer’s patients. By using the proprietary AβCC technology, Alzinova can develop therapies that are unique in that they target Alzheimer’s disease-driving toxins of Aβ (“oligomers”) specifically.
-
Episode 83 - Joy Clark - Chief People Officer Worldwide Clinical Trials
29 oktober 2025 · 27 min
Welcome to The Biohub Lees meer
Joy Clark, Chief People Officer at Worldwide Clinical Trials, joins The BioHub Podcast to talk about building belonging, leading with purpose, and driving health equity in clinical research. Joy shares her journey from high-growth tech to the CRO world, how Worldwide has cultivated a culture that’s 73% women, and why human-centered leadership matters more than ever.
-
Episode 82 - Heather Turner - CEO LB Pharmaceuticals
28 oktober 2025 · 24 min
We were thrilled to welcome, Heather Turner, CEO of LB Pharmaceuticals, onto The BioHub. Heather is a seasoned biotechnology executive with over 25 years of experience driving legal, operational, and strategic excellence across the biopharmaceutical industry. She currently serves as CEO of LB Pharmaceuticals, a clinical-stage company focused on innovative treatments for schizophrenia. Under her leadership, LB recently went public in a landmark IPO, marking a major milestone in the company’s growth journey. Lees meer
Prior to LB, Heather led Carmot Therapeutics through a $3.1 billion acquisition by Roche, expanded teams, and executed transformative financing and strategic initiatives. With deep expertise in navigating complex biotech landscapes, Heather’s insights span corporate strategy, IPOs, and driving innovation in clinical-stage development. We’re excited to hear her perspective on leadership, biotech growth, and the future of medicine
-
Episode 81 - Clarke Attwell - CEO Claris Biotherapeutics
27 oktober 2025 · 20 min
Today, we’re joined by Clarke Atwell, CEO of Claris Biotherapeutics — a company pioneering regenerative biologic therapies with a focus on transforming the field of ophthalmology.Under Clarke’s leadership, Claris has achieved a major milestone with its Series A financing, fueling the company’s mission to advance novel therapies designed to repair and restore vision at the cellular level, and are now in the process of going through there series B round. By combining cutting-edge biology with a deep understanding of ocular disease, Claris is working to address some of the most challenging conditions in eye health.Clarke’s career spans scientific innovation and executive leadership across the biopharma industry, and he now leads Claris through an exciting new chapter of growth and clinical translation. Lees meer
-
Episode 80 - Dr. Maurits Geerlings - CEO Nanocell
23 oktober 2025 · 28 min
Today I’m joined by Dr. Maurits Geerlings, President and CEOof NanoCell Therapeutics. Lees meer
Maurits is a true biotech entrepreneur — he’s co-founded and built multiple companies including Actinium Pharmaceuticals, Formula Pharmaceuticals, and Mirata Pharma — and now he’s on a mission to revolutionize in-vivo cell engineering.
In this conversation, we dive into Maurits’ journey, the unique structure of NanoCell, the challenges and opportunities in cell therapy right now, and his bold vision for the future of this field.
Enjoy and stay tuned.
-
Episode 79 - Amir Inamdar - Cybin Inc
21 oktober 2025 · 34 min
Amir Inamdar is the Chief Medical Officer at Cybin Inc., bringing more than 20 years of clinical medicine and drug-development experience. Prior to joining Cybin, Amir held senior roles in industry including Senior Medical Director for R&D Neurosciences at AstraZeneca, Medical Director at Takeda Development Centre Europe Ltd., and Director of Clinical Pharmacology & Discovery Medicine at GlaxoSmithKline. He's led global teams in advancing novel therapies across indications such as treatment-resistant depression, narcolepsy, anxiety, schizophrenia, bipolar disorder and substance-use disorders — and steered compounds from preclinical development through first-in-human and proof-of-concept studies Lees meer
-
Episode 78 - Dena House - CPO Adverum
14 oktober 2025 · 25 min
Today I’m joined by Dena House - Chief People Officer atAdverum Biotechnologies. Lees meer
Dena’s career has spanned some of the world’s leading life sciences companies, from Nikon Precision to Myriad Genetics, but what stands out is her passion for building strong, intentional culture in complex organizations.
At Adverum, she was brought in with a clear mission: buildthe kind of people-first culture that can power innovation, resilience, and long-term growth, even in one of biotech’s toughest markets.
We talk about how she tackled that challenge, what greatculture actually looks like in biotech, and why this work matters more now than ever.
Let’s get into it.
-
Episode 77 - Baruch Harris - COO of Pretzel Therapeutics
9 oktober 2025 · 18 min
We were delighted to welcome Baruch Harris, Chief Operating Officer at Pretzel Therapeutics, a company dedicated to translating mitochondrial biology into transformative therapies. Dr. Harris’s journey spans from rigorous scientific roots to strategic leadership — he holds a Ph.D. in Biochemistry and Molecular Biology from UCSF and a degree in Biophysics from Brown University. Before joining Pretzel, he led business development, operations, and fundraising efforts at companies including ROME Therapeutics, Yumanity Therapeutics, Metera Pharmaceuticals, and Enlight Biosciences. In our conversation today, we’ll explore how Pretzel is tackling mitochondrial dysfunction as a therapeutic target, the unique operational challenges of scaling a biotech platform grounded in mitochondrial biology. Lees meer
-
Episode 76 - Abid Ansari - CFO of General Oncology
8 oktober 2025 · 26 min
Welcome back to another episode of The BioHub, we were delighted to welcome on Abid Ansari, Chief Financial Officer at General Oncology, a clinical-stage biopharma company focused on first-in-class therapies for metastatic cancer. With more than two decades of experience in the biotechnology and life sciences sectors, Abid has built his reputation as a strategic finance executive who bridges capital, innovation, and growth. Over his career, he’s led major capital raises — including a $153 million Series C at Artios and a $146 million IPO at Precision BioSciences — and driven business development deals, licensing agreements, and M&A transactions. Earlier in his journey, Abid held roles at GSK in deal finance and portfolio management, contributing to high-stakes transactions such as the acquisition of Bristol Myers Squibb’s HIV portfolio and licensing agreements with Adaptimmune Lees meer
-
Episode 75 - Paul Song - CEO of NKGen
7 oktober 2025 · 32 min
I’m joined by Dr. Paul Song, Chairman & CEO of NKGen Biotech. Lees meer
Paul has led across biotech, from CMO at NKGEN to co-founding Fuse Biotherapeutics and since 2022 he’s been driving NKGen’s mission to harness natural killer cells through their proprietary SNK platform for neurodegenerative diseases and cancer.
In this episode, we dive into his decision to return and lead NKGen, the science behind the SNK platform, the company’s recent SPAC merger and NASDAQ listing, and his perspective on building resilient biotech companies in today’s market.Enjoy and stay tuned.
-
Episode 74 - Roy Maute - CEO of Pheast Therapeutics
30 september 2025 · 30 min
On this episode we had the pleasure of featuring Roy Maute of Pheast Therapeutics. Lees meer
Pheast are unleashing the power of macrophages in oncology, starting in advanced solid tumours & Ovarian Cancer. Their pipeline consists of novel innate immune checkpoint inhibitors (incl. Anti-CD24), based on research out of Irv Weissman's lab at Stanford.
In this episode we cover the inspiration behind Roy's career in oncology R&D & the origins of Pheast's name & platform, before moving onto Pheast's recent (FTD, ph1 entry) and upcoming milestones. We also cover their big ambitions for the future & how their huge focus on culture as a business has & continues to shape their journey.
-
Episode 73 - Tatiana Novobrantseva - CSO of NextPoint Therapeutics
30 september 2025 · 40 min
Today, we're joined by Dr. Tatiana Novobrantseva, the Chief Scientific Officer at NextPoint Therapeutics, a clinical-stage biotech company pioneering precision immuno-oncology therapies targeting the novel HHLA2 (B7-H7) pathway.Tatiana brings over two decades of expertise in immunology, cancer, immuno-oncology, autoimmunity, and fibrosis. She co-founded Verseau Therapeutics in 2017, serving as CSO and advancing novel immunotherapies that stimulate macrophage repolarization to initiate anti-cancer immune responses. Prior to that, she led oncology discovery and development projects at Moderna as Chief Scientific Officer, Immuno-Oncology Research.At NextPoint, Tatiana is leading the development of therapies targeting the B7-H7 immune checkpoint pathway, aiming to reactivate exhausted T and NK cells in solid tumors. This approach offers a promising alternative for patients who have not responded to traditional PD-1/CTLA-4 therapies.Dr. Novobrantseva earned her Ph.D. in immunology from the University of Cologne in Germany and completed postdoctoral research at Harvard Medical School in the laboratory of Dr. Klaus Rajewsky, focusing on B cell immunology and autoimmunity Lees meer
-
Episode 72 - Nick Manusos - CEO of Kenai Therapeutics
25 september 2025 · 26 min
Welcome back to another episode of The BioHub, we weredelighted to welcome on Nick Manusos, the CEO of Kenai Therapeutics, a pioneering biotech company developing neuron replacement therapies for neurological disorders. Nick’s journey spans decades of innovation and leadership—from senior roles at global pharma giants like Baxter, Takeda, and Abbott, to founding and leading cutting-edge startups like Iota Biosciences and Opsis Therapeutics. Under his guidance, Kenai Therapeutics has secured groundbreaking funding and is advancing life-changing therapies for patientswith Parkinson’s disease. He holds an MBA from Northwestern University’s Lees meer
Kellogg School of Management and a BBA from the University of Wisconsin, bringing a rare combination of business acumen and scientific vision to the table. Nick joins us today to share his insights on pioneering stem celltherapies, building biotech startups from the ground up, and what it takes to turn cutting-edge science into real-world solutions.
-
Episode 71 - Punit Dhillon - CEO of Skye Bioscience
24 september 2025 · 52 min
Today’s guest is someone who’s seen biotech from both sidesof the table—first as an investor, and now as a builder. Lees meer
I’m joined by Punit Dhillon, CEO of Skye Bioscience, wherehe’s leading one of the most exciting stories in metabolic health.
Punit started Skye as employee number one and has sincebuilt it into a clinical-stage company with one first-in-class programs and backing from major life science investors like 5AM and Versant. With a background in finance and business development—and a career that includes partnerships with Merck, Genentech, BMS and Pfizer—he brings a unique anddeeply strategic lens to biotech leadership.
In this episode, we dig into the mindset it takes to buildfrom the ground up, the wave of innovation in obesity, and how Skye is carving out its own lane in one of the most competitive markets in biotech.
-
Episode 70 - Paula Soteropoulos
24 september 2025 · 28 min
We were delighted to welcome Paula Soteropoulos, Chairman of the Board at Ensoma and Venture Partner at 5am Ventures, onto The BioHub. Paula is a seasoned leader whose career spans some of the most influential companies in the industry and she's played a pivotal role in shaping the biotechlandscape over the past few decades She began her journey at Genzyme, where she spent nearly two decades helping bring transformative therapies to patients. Lees meer
She later took on leadership roles at Moderna during itsearly days. Paula went on to serve as CEO of Akcea Therapeutics, steering the company as it developed medicines for rare diseases, and today she serves asExecutive Chair of Ensoma, a company pioneering a new generation of in vivo gene therapies designed to reach far more patients than ever before, and also serves as a Venture Partner at 5am Ventures.
Join us in this episode as we talk through Paula's journey,company building, Ensoma's first IND approval & her role at 5am Ventures.
-
Episode 69 - Nolan Townsend - CEO of Lexeo Therapeutics
18 september 2025 · 34 min
Welcome back to another episode of The BioHub, we were thrilled to welcome on Nolan Townsend, CEO of Lexeo Therapeutics.Nolan has been at the helm of Lexeo since January 2020, leading a clinical-stage genetic medicine company aiming to transform treatment for genetically-defined cardiovascular diseases and APOE4-associated Alzheimer’s disease. Lees meer
Under his leadership, Lexeo has built a pipeline of therapies rooted in breakthrough science, partnered with prominent academic institutions like Weill Cornell Medicine, and raised significant capital to support its mission. Before Lexeo, Nolan spent more than a decade at Pfizer, where he was President of Pfizer Rare Disease for North America, and also President for its International Rare Disease operations — overseeing strategy, cross-functional teams, and large operating budgets.
-
Episode 68 – Stefan Lutz – Codexis
16 september 2025 · 31 min
Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Dr. Stefan Lutz, SVP of Research at Codexis—a leader in enzyme engineering and the force behind some of the most exciting advancements in RNA manufacturing.
Stefan’s journey spans academia and industry, from chairing the Chemistry Department at Emory University to now driving innovation at Codexis. He and his team are helping solve some of biotech’s biggest challenges—from improving RNA synthesis to using AI to unlock new frontiers in protein engineering.
This one’s all about the evolution of RNA, the role of AI in discovery, and what it takes to lead with a growth mindset in modern science.
Enjoy and stay tuned.
-
Episode 67 - Micah Mackison - CEO of Vico Therapeutics
16 september 2025 · 22 min
Thanks for tuning into another episode of The BioHub, we were delighted to welcome on Micah Mackison who serves as the Chief Executive Officer of Vico Therapeutics, a company blazing trails in genetic neurology with RNA-based medicines. Since taking the helm in August 2022, Micah has been leading Vico’s drive to translate novel oligonucleotide RNA-modulating therapies from the lab into clinical trials, particularly in disorders like Huntington’s disease and spinocerebellar ataxia. Before Vico, Micah served as Chief Business Officer and EVP of Strategy & Corporate Development at Locanabio, a gene therapy company targeting neurological disease, where he played a key role in strategy setting, capital-raising, and organizational development. Prior roles include senior leadership in corporate development and strategy at Assembly Biosciences; heading new ventures and corporate strategy in neuroscience at Lundbeck; and before that, leading M&A & corporate development at Ovation Pharmaceuticals — the company that launched the first product for Huntington’s disease. Early in his career, he worked in finance with Eli Lilly and Pfizer. At Vico, Micah is particularly focused on advancing their lead candidate VO659, an antisense oligonucleotide that aims to slow or halt progression in CAG-repeat neurological diseases, and on growing the company’s proprietary VICOMER™ platform for RNA modulation Lees meer
-
Episode 66 - Andy Parker - CEO of Step Pharma
9 september 2025 · 28 min
Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. Lees meer
Today I’m joined by Andy Parker, the CEO of Step Pharma.
Andy has spent over two decades in biotech and pharma,holding senior leadership roles at companies like AstraZeneca, Shire and Zealand Pharma and even spending time on the VC side at Eclosion.
Since 2019, he’s been leading Step Pharma, a companydeveloping first-in-class CTPS1 inhibitors, with their lead program now in the clinic for cancer.
We talk about the science behind Step’s approach, what’snext for the company, and Andy’s experience moving from big pharma to small biotech. Plus: lessons on fundraising in today’s market and building a great work culture.Enjoy and stay tuned.
-
Episode 65 - Robert Ross - CEO of Clasp Therapeutics
4 september 2025 · 28 min
We were delighted to welcome Robert Ross, Chief Executive Officer at Clasp Therapeutics, onto The BioHub. Clasp Therapeutics are a pioneering biotech company spearheading the next generation of T-cell engager therapies. Founded in 2024 and backed by a successful $150 million Series A round with top tier investors, Clasp stands out for its novel approach in delivering off-the-shelf, bispecific T‐cell engagers that narrowly target cancer-driving mutations while sparing healthy tissues. Dr. Ross brings a wealth of experience to Clasp’s mission. Before stepping into the CEO role at Clasp in November 2023, he led Surface Oncology through its acquisition by Coherus Biosciences and directed oncology strategy at bluebird bio, where he played a key role in advancing groundbreaking CAR T-cell therapies.In this episode we dive into inspiration behind the founding of Clasp, what it takes to build a biotech and the shift from preclinical to clinical, an insight into some of the work Clasp are doing, as well as Rob transitioning from a practicing Oncologist to a Biotech CEO. Lees meer
-
Episode 64 - Kristof Vercruysse - CEO of TargED Biopharmaceuticals
28 augustus 2025 · 30 min
Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. Lees meer
On this episode we were joined by Kristof Vercruysse, CEO of TargED Biopharmaceuticals, an Utrecht-based biotech who're developing a novel Targeted Enzyme Delivery approach to Thrombolysis.
On this episode, we discuss the current standard of care in indications such as TTP & Acute Ischemic Stroke and why TargED's platform represents a potential paradigm-shift for patients.
-
Episode 63 - Aaron Kantoff – Co-Founder of Scion Life Sciences
26 augustus 2025 · 27 min
I am conscious that I redo the ontro here - Please excuse Lees meer
Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry.
I’m joined by Aaron Kantoff — Co-Founder and Managing Partner at Scion Life Sciences.
Aaron helped build the therapeutics group at Apple Tree Partners from scratch, co-founding 11 companies along the way. After leaving Apple tree, Aaron co-founded RayzeBio, which was acquired by BMS for $4.1B.
Now at Scion, he's continuing to back and build bold biotech companies with long-term potential — and a fresh approach to VC.
We talk about the companies he’s built, what he’s learned from them, and why Scion is doubling down on science-first biotech in today’s market.
Enjoy and stay tuned.
-
Episode 62 - Alison Finger – COO Vicero Bio
21 augustus 2025 · 15 min
Today, we’re delighted to welcome Alison Finger, MBA, the Chief Operating Officer at Vicero Bio—a preclinical-stage biotech company pioneering VINCOBODY therapies, a next-generation nanobody platform being developed to tackle immune-mediated diseases and cancer. Since stepping into the COO role in September 2023, Alison has been at the helm of Vicero’s business operations, steering strategic and financial planning, company build-out, and business development initiatives.Prior to Vicero, Alison spent several years as Chief Commercial Officer at bluebird bio, where she led global strategy and commercialization for transformative gene and cell therapy products. Earlier in her career, she held multiple leadership roles at Bristol-Myers Squibb—including Managing Director for Australia/New Zealand and global franchise leadership in oncology, neurology, and virology—where she guided portfolio development and global launches across geographies.Join us in this episode at we talk through details on the pipeline, the lead programme and how the Series A raise is coming along, being in commercial roles for the bulk of her career and how the transition to more of an operating role is. Lees meer
-
Episode 61 - Rick Winningham – CEO Theravance
14 augustus 2025 · 33 min
Welcome to The BioHub podcast, where we interview the top minds from across the Biotech and Pharma industry. Lees meer
I’m joined by Rick Winningham, Chairman and CEO of Theravance Biopharma.
Rick has led Theravance since its spin-out from Innoviva in 2014, after serving as CEO of Innoviva and holding senior leadership roles at Bristol Myers Squibb. He’s also been a driving force in industry advocacy, chairing the California Life Sciences Association and serving on the boards of Jazz Pharmaceuticals, Rivus, and BIO.
At Theravance, he’s steering strategy, innovation, and execution in a challenging market — drawing on decades of experience to navigate cycles, build strong teams, and keep advancing transformative medicines.
Enjoy and stay tuned.
-
Episode 60 – Devyn Smith – CEO Arbor Biotechnologies
31 juli 2025 · 24 min
Welcome back to another episoe of The Bio Hub, we were delighted to be joined by Dr. Devyn Smith, a widely respected executive and thought leader in the field of cell and gene therapy, with a career that spans both global pharmaceutical giants and pioneering biotech startups.Devyn is currently the Chief Executive Officer of Arbor Biotechnologies, a company at the forefront of next-generation gene editing, co-founded by CRISPR pioneer Feng Zhang. Arbor is developing a proprietary platform of CRISPR-based editors and therapeutic programs aimed at tackling serious genetic diseases, with a focus on in vivo delivery and precision editing.Before joining Arbor, Devyn served as Chief Operating Officer at Sigilon Therapeutics, where he helped guide the company through its IPO and led its strategic and operational functions, including clinical, manufacturing, and regulatory efforts. Prior to that, he held multiple senior roles at Pfizer, including Head of Strategy for the Rare Disease Research Unit and Chief of Staff to the President of Worldwide R&D.Beyond the executive suite, Devyn serves as a board member Alliance for Regenerative Medicine (ARM), where he played a key role in advocating for science-forward policy, expanding regulatory frameworks for advanced therapies, and pushing for sustained federal funding in biomedical research. He remains an active voice in the industry on issues ranging from AAV development and IND readiness to market access and public trust in gene-editing technologies.Devyn holds a Ph.D. in Genetics and Molecular Biology from the University of North Carolina and began his career in research before transitioning into strategy, development, and executive leadership. Lees meer
-
Episode 59 – Gerardo Ubaghs Carrion – CFO Frontier Medicines
31 juli 2025 · 33 min
Welcome to the BioHub podcast where we interview the top minds from across the Biotech and Pharma industry.I’m joined by Gerardo Ubaghs, CFO of Frontier Medicines. Lees meer
Gerardo has had one of the most unique career journeys you’ll hear — from being a professional violinist, to working in investment banking, and then stepping into biotech where he’s helped build and finance some of the most innovative companies out there.
At Frontier, he’s driving strategy and finance for their mission to unlock previously undruggable targets using chemoproteomics and AI to develop precision medicines.
Enjoy and stay tuned.
-
Episode 58– Dan Kemp (CEO) & Steven Katz- (CMO) of Shinobi Therpaeutics
29 juli 2025 · 30 min
Welcome back to another episode of The Bio Hub, we were delighted to be joined by two leaders from Shinobi Therapeutics, a company pushing the boundaries of off-the-shelf cell therapy through an innovative stealth cell platform that aims to overcome immune rejection and unlock the full potential of allogeneic CAR-T and CAR-NK therapies."With us is Dr. Dan Kemp, CEO of Shinobi Therapeutics. Dan brings over two decades of experience at the intersection of science and business in the cell and gene therapy space. He earned his PhD in molecular pharmacology from the University of Kent, completed postdoctoral work at Massachusetts General Hospital, and held an HHMI fellowship at Harvard Medical School. His industry leadership spans major roles at Takeda, where he helped shape the company’s cell therapy strategy, and as CEO of Wugen, where he advanced off-the-shelf NK and CAR-T therapies through key stages of developmentAlso with us is Dr Steven Katz, a medical oncologist and physician-scientist with a long-standing focus on immuno-oncology and cellular therapies. Before joining Shinobi, Dr. Katz held leadership roles guiding early clinical development and translational strategy at TriSalus Life Sciences. His work has consistently centered on designing and executing clinical trials that bring advanced therapies—especially cell-based treatments—closer to patients. Now at Shinobi, he plays a critical role in shaping the company’s clinical vision, steering development programs for immune-evasive, off-the-shelf cell therapies, and leading efforts to move first-in-class products into the clinic. Lees meer
-
Alex Blyth - CEO LifT Biosciences at BIO Boston 2025
22 juli 2025 · 16 min
From BIO Boston: Alex Blyth, CEO of LifT Biosciences Lees meer
In this powerful opening episode from BIO 2025, I sit down with Alex Blyth, the founder and CEO of LifT Biosciences — a company re-engineering the immune system to finally beat cancer at its own game.
We talk about:
Why targeted therapies are failing most patients
What tumour escape is and why it’s the real enemy
How LiFt’s “super neutrophils” could be the Keytruda of innate immunity
And the personal loss that pushed Alex to rethink everything we know about cancer treatment
Alex’s story is sharp, ambitious, and deeply personal — exactly the kind of leadership biotech needs right now.
This is the first in a series of in-person interviews from BIO Boston with some of the sharpest founders and execs in the industry.
Stay tuned — more to come.